Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy

AIDS Research and Human Retroviruses

Volumn 23, Issue 5, 2007, Pages 741-747

  Sriram, Uma ^a,c   Wong, Michael ^a   Caillier, Stacy J ^a   Hecht, Frederick M ^b   Elkins, Mary K ^a   Levy, Jay A ^a   Oksenberg, Jorge R ^a   Baranzini, Sergio E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; RNA; T LYMPHOCYTE RECEPTOR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; MONOTHERAPY; MULTIGENE FAMILY; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; GENES, T-CELL RECEPTOR BETA; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; POLYMERASE CHAIN REACTION;

EID: 34249903913     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0209     Document Type: Article

References (26)

1. Pantaleo G, Demarest JF, Soudeyns H, et al.: Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994;370:463-467.
2. Pantaleo G, Soudeyns H, Demarest JF, et al.: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-9853.
3. Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
4. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
5. Gorochov G, Neumann AU, Kereveur A, et al.: Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998;4:215-221.
6. Soudeyns H, Champagne P, Holloway CL, et al.: Transient T cell receptor beta-chain variable region-specific expansions of CD4+ and CD8+ T cells during the early phase of pediatric human immunodeficiency virus infection: Characterization of expanded cell populations by T cell receptor phenotyping. J Infect Dis 2000;181:107-120.
7. Schito AM, Vittinghoff E, Hecht FM, et al.: Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy. Blood 2001;97:214-220.
8. Gorski J, Yassai M, Zhu X, et al.: Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994;152:5109-5119.
9. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, and Oksenberg JR: B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999:163:5133-5144.
10. Baranzini SE, Laxer K, Saketkhoo R, et al.: Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis. Neurology 2002;58:709-716.
11. Martinez-Marino B. Ashlock BM, Shiboski S. Hecht FM, and Levy JA: Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol 2004;24:135-144.
12. Levy Y, Durier C, Krzysiek R. et al.: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS 2003;17:343-351.
13. Arno A. Ruiz L, Juan M, et al.: Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with
14. Dybul M, Hidalgo B, Chun TW, et al.: Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HlV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002;185:61-68.
15. Losso MH, Belloso WH. Emery S. et al.: A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J Infect Dis 2000;181:1614-1621.
16. Abrams DI, Bebchuk JD. Denning ET, et al.: Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059. J Acquir Immune Defic Syndr 2002;29:221-231.
17. Davey RT, Jr, Murphy RL, Graziano FM, et al.: Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 2000;284:183-189.
18. Hengge UR, Goos M, Esser S, et al.: Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998;12.F225-234.
19. Elkins MK, Vittinghoff E, Baranzini SE, et al.: Longitudinal analysis of B cell repertoire and antibody gene rearrangements during early HIV infection. Genes Immun 2005;6:66-69.
20. Baranzini SE, Elfstrom C, Chang SY, et al.: Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000;165:6576-6582.
21. Vandesompele J, De Prefer K, Pattyn F, et al.: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002.3.RESEARCH0034.
22. Giovannetti A, Pierdominici M, Marziali M, et al.: Persistently biased T-cell receptor repertoires in HIV-1-infected combination antiretroviral therapy-treated patients despite sustained suppression of viral replication. J Acquir Immune Defic Syndr 2003;34:140-154.
23. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995:332:567-575.
24. Martinez-Marino B, Shiboski S, Hecht FM, Kahn JO, and Levy JA: Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS 2004;18:1991-1999.
25. Kovacs JA, Lempicki RA, Sidorov IA, et al.: Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005;115:2139-2148.
26. Levy Y, Gahery-Segard H, Durier C, et al.: Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005;19:279-286.